| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart, Artificial | 4 | 2020 | 35 | 2.90 | Why? |
| von Willebrand Factor | 6 | 2021 | 668 | 1.85 | Why? |
| Bioprosthesis | 3 | 2017 | 126 | 1.82 | Why? |
| Endothelial Progenitor Cells | 2 | 2020 | 103 | 1.33 | Why? |
| Endothelial Cells | 8 | 2021 | 2048 | 1.33 | Why? |
| Vascular Endothelial Growth Factor A | 3 | 2021 | 604 | 1.25 | Why? |
| Angiopoietin-2 | 3 | 2021 | 125 | 0.91 | Why? |
| Neovascularization, Physiologic | 4 | 2015 | 160 | 0.87 | Why? |
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 66 | 0.85 | Why? |
| Myelopoiesis | 1 | 2021 | 116 | 0.85 | Why? |
| Antigens, CD19 | 1 | 2020 | 98 | 0.84 | Why? |
| Endothelium, Vascular | 5 | 2021 | 1751 | 0.74 | Why? |
| Lupus Coagulation Inhibitor | 1 | 2021 | 262 | 0.74 | Why? |
| Epoprostenol | 2 | 2015 | 41 | 0.72 | Why? |
| Hemorheology | 1 | 2017 | 17 | 0.71 | Why? |
| Neovascularization, Pathologic | 1 | 2021 | 305 | 0.68 | Why? |
| Antithrombins | 2 | 2018 | 353 | 0.68 | Why? |
| ADAMTS13 Protein | 1 | 2021 | 363 | 0.67 | Why? |
| Stem Cells | 3 | 2019 | 595 | 0.66 | Why? |
| Dabigatran | 2 | 2018 | 204 | 0.65 | Why? |
| Angiogenesis Inducing Agents | 1 | 2015 | 11 | 0.62 | Why? |
| Thrombosis | 5 | 2021 | 7504 | 0.61 | Why? |
| von Willebrand Diseases | 1 | 2017 | 81 | 0.61 | Why? |
| Paracrine Communication | 1 | 2015 | 73 | 0.57 | Why? |
| Hemolysis | 1 | 2017 | 283 | 0.56 | Why? |
| Hindlimb | 1 | 2013 | 21 | 0.55 | Why? |
| Interleukin-8 | 2 | 2019 | 964 | 0.55 | Why? |
| Hemostasis | 2 | 2020 | 811 | 0.55 | Why? |
| Forearm | 1 | 2013 | 52 | 0.53 | Why? |
| Hematologic Diseases | 1 | 2021 | 614 | 0.53 | Why? |
| Adult Stem Cells | 1 | 2013 | 68 | 0.52 | Why? |
| Vascular Resistance | 1 | 2013 | 148 | 0.48 | Why? |
| Venous Thromboembolism | 6 | 2021 | 4273 | 0.46 | Why? |
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 595 | 0.46 | Why? |
| Ischemia | 3 | 2013 | 901 | 0.42 | Why? |
| Drug Resistance | 1 | 2013 | 395 | 0.42 | Why? |
| Multipotent Stem Cells | 1 | 2009 | 9 | 0.41 | Why? |
| Hemorrhage | 3 | 2018 | 3013 | 0.38 | Why? |
| Tissue Culture Techniques | 1 | 2009 | 158 | 0.37 | Why? |
| Venous Thrombosis | 2 | 2021 | 2739 | 0.37 | Why? |
| Paris | 3 | 2021 | 1287 | 0.36 | Why? |
| Endoglin | 2 | 2017 | 16 | 0.36 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.35 | Why? |
| Cell Proliferation | 1 | 2015 | 1973 | 0.34 | Why? |
| Hypertension, Pulmonary | 2 | 2015 | 970 | 0.34 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.31 | Why? |
| Antihypertensive Agents | 2 | 2015 | 1962 | 0.30 | Why? |
| Biomarkers | 12 | 2021 | 23361 | 0.28 | Why? |
| Cells, Cultured | 5 | 2019 | 5835 | 0.27 | Why? |
| Anticoagulants | 5 | 2021 | 9563 | 0.27 | Why? |
| Mice, Nude | 2 | 2015 | 340 | 0.26 | Why? |
| Cardiac Surgical Procedures | 1 | 2017 | 1931 | 0.26 | Why? |
| Heart Defects, Congenital | 1 | 2013 | 933 | 0.26 | Why? |
| Kaplan-Meier Estimate | 3 | 2021 | 4260 | 0.25 | Why? |
| Cell Differentiation | 3 | 2015 | 1338 | 0.24 | Why? |
| Fibrin Fibrinogen Degradation Products | 4 | 2021 | 5993 | 0.23 | Why? |
| Fibroblast Growth Factor 2 | 1 | 2021 | 77 | 0.23 | Why? |
| Cell Lineage | 2 | 2015 | 241 | 0.22 | Why? |
| Receptors, Formyl Peptide | 1 | 2020 | 26 | 0.22 | Why? |
| Placenta Growth Factor | 1 | 2021 | 93 | 0.22 | Why? |
| E-Selectin | 1 | 2020 | 55 | 0.21 | Why? |
| Molecular Weight | 1 | 2021 | 249 | 0.21 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.21 | Why? |
| Blood Platelets | 3 | 2018 | 1704 | 0.20 | Why? |
| Proportional Hazards Models | 3 | 2021 | 6543 | 0.20 | Why? |
| Collagen | 1 | 2021 | 222 | 0.20 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.20 | Why? |
| Blood Coagulation | 3 | 2021 | 2768 | 0.19 | Why? |
| Hospital Mortality | 6 | 2021 | 22087 | 0.18 | Why? |
| Activin Receptors, Type II | 1 | 2017 | 20 | 0.18 | Why? |
| Pulsatile Flow | 1 | 2018 | 123 | 0.18 | Why? |
| Middle Aged | 23 | 2021 | 270681 | 0.17 | Why? |
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 8 | 0.17 | Why? |
| Equipment Failure Analysis | 1 | 2017 | 94 | 0.17 | Why? |
| Plague | 1 | 2020 | 155 | 0.17 | Why? |
| Proteomics | 2 | 2020 | 2481 | 0.17 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.17 | Why? |
| Male | 26 | 2021 | 367725 | 0.17 | Why? |
| Primary Cell Culture | 1 | 2019 | 501 | 0.17 | Why? |
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2017 | 51 | 0.17 | Why? |
| Thromboembolism | 2 | 2021 | 2101 | 0.16 | Why? |
| Prospective Studies | 8 | 2021 | 43301 | 0.16 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.16 | Why? |
| Aged | 17 | 2021 | 215776 | 0.16 | Why? |
| Female | 23 | 2021 | 380317 | 0.16 | Why? |
| Extracorporeal Circulation | 1 | 2018 | 130 | 0.16 | Why? |
| Arterial Pressure | 1 | 2018 | 208 | 0.16 | Why? |
| Cattle | 2 | 2019 | 1336 | 0.15 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.15 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.15 | Why? |
| Humans | 40 | 2021 | 930598 | 0.15 | Why? |
| Shock, Cardiogenic | 2 | 2021 | 700 | 0.15 | Why? |
| Cell Communication | 1 | 2017 | 396 | 0.15 | Why? |
| Janus Kinase 2 | 1 | 2017 | 218 | 0.14 | Why? |
| Patient Admission | 3 | 2021 | 5250 | 0.14 | Why? |
| Prosthesis Implantation | 1 | 2017 | 261 | 0.14 | Why? |
| Protein Multimerization | 1 | 2021 | 1336 | 0.14 | Why? |
| Materials Testing | 1 | 2017 | 380 | 0.14 | Why? |
| France | 6 | 2021 | 12074 | 0.14 | Why? |
| Severity of Illness Index | 9 | 2021 | 48226 | 0.14 | Why? |
| Prosthesis Design | 1 | 2017 | 594 | 0.14 | Why? |
| Urologic Neoplasms | 1 | 2018 | 348 | 0.13 | Why? |
| Shock | 1 | 2021 | 1868 | 0.13 | Why? |
| Thrombophilia | 3 | 2021 | 1935 | 0.13 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 314 | 0.13 | Why? |
| Endothelin Receptor Antagonists | 1 | 2013 | 47 | 0.13 | Why? |
| Immunomagnetic Separation | 1 | 2013 | 55 | 0.13 | Why? |
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 68 | 0.13 | Why? |
| Phosphodiesterase 5 Inhibitors | 1 | 2013 | 104 | 0.12 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2019 | 552 | 0.12 | Why? |
| Factor Xa Inhibitors | 1 | 2017 | 490 | 0.12 | Why? |
| Transfection | 1 | 2015 | 864 | 0.12 | Why? |
| Hematology | 1 | 2019 | 649 | 0.12 | Why? |
| Pulmonary Medicine | 1 | 2019 | 706 | 0.12 | Why? |
| RNA Interference | 1 | 2015 | 534 | 0.12 | Why? |
| Adult | 15 | 2021 | 244371 | 0.12 | Why? |
| Nuclear Medicine | 1 | 2019 | 585 | 0.11 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.11 | Why? |
| Respiration Disorders | 1 | 2017 | 526 | 0.11 | Why? |
| Prognosis | 5 | 2021 | 32490 | 0.11 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.11 | Why? |
| Thromboangiitis Obliterans | 1 | 2009 | 1 | 0.11 | Why? |
| Bone Morphogenetic Protein 4 | 1 | 2009 | 6 | 0.10 | Why? |
| Receptors, CXCR | 1 | 2009 | 8 | 0.10 | Why? |
| Vasodilator Agents | 1 | 2013 | 344 | 0.10 | Why? |
| Carbon Dioxide | 1 | 2017 | 917 | 0.10 | Why? |
| Bone Morphogenetic Protein 2 | 1 | 2009 | 24 | 0.10 | Why? |
| ABO Blood-Group System | 1 | 2019 | 995 | 0.10 | Why? |
| Administration, Oral | 2 | 2017 | 2340 | 0.10 | Why? |
| Receptor, PAR-1 | 1 | 2009 | 24 | 0.10 | Why? |
| Chemokine CXCL12 | 1 | 2009 | 74 | 0.10 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.10 | Why? |
| Cell Survival | 1 | 2015 | 1581 | 0.10 | Why? |
| Liver | 2 | 2021 | 4007 | 0.10 | Why? |
| Animals | 9 | 2019 | 78931 | 0.09 | Why? |
| Autoantibodies | 1 | 2020 | 2094 | 0.09 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.09 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.09 | Why? |
| Antibodies | 1 | 2015 | 846 | 0.09 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.09 | Why? |
| Cell-Derived Microparticles | 1 | 2009 | 134 | 0.09 | Why? |
| Anesthesiology | 1 | 2019 | 1163 | 0.09 | Why? |
| Stem Cell Transplantation | 1 | 2013 | 531 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.09 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.08 | Why? |
| Blood Transfusion | 1 | 2017 | 1399 | 0.08 | Why? |
| Fatal Outcome | 1 | 2017 | 3438 | 0.08 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.08 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.08 | Why? |
| Up-Regulation | 1 | 2015 | 2249 | 0.08 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.08 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.08 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.08 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.08 | Why? |
| Thrombin | 1 | 2009 | 325 | 0.08 | Why? |
| Autopsy | 1 | 2017 | 3495 | 0.07 | Why? |
| Dose-Response Relationship, Drug | 1 | 2015 | 3776 | 0.07 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.07 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.07 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| DNA-Binding Proteins | 2 | 2017 | 469 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.07 | Why? |
| Infant | 3 | 2021 | 30274 | 0.07 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.06 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.06 | Why? |
| Case-Control Studies | 3 | 2020 | 17671 | 0.06 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.06 | Why? |
| Transplant Recipients | 1 | 2019 | 4982 | 0.06 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.06 | Why? |
| Mice | 2 | 2013 | 21357 | 0.06 | Why? |
| Child | 5 | 2021 | 70012 | 0.06 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.06 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.05 | Why? |
| Transcription Factors | 2 | 2017 | 784 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.05 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Mutation | 2 | 2017 | 12376 | 0.05 | Why? |
| Swine | 2 | 2019 | 3352 | 0.05 | Why? |
| Tachycardia | 1 | 2020 | 239 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Cardiotonic Agents | 1 | 2021 | 418 | 0.05 | Why? |
| CD40 Ligand | 1 | 2018 | 121 | 0.05 | Why? |
| Lactic Acid | 1 | 2021 | 393 | 0.05 | Why? |
| Peptide Fragments | 1 | 2009 | 2075 | 0.05 | Why? |
| Signal Transduction | 1 | 2015 | 7207 | 0.04 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.04 | Why? |
| Stress, Mechanical | 1 | 2018 | 143 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2017 | 72 | 0.04 | Why? |
| Antidotes | 1 | 2017 | 46 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Vasoconstrictor Agents | 1 | 2021 | 714 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.04 | Why? |
| Longevity | 1 | 2019 | 159 | 0.04 | Why? |
| Platelet Function Tests | 1 | 2018 | 231 | 0.04 | Why? |
| P-Selectin | 1 | 2018 | 224 | 0.04 | Why? |
| Cell Adhesion | 1 | 2017 | 230 | 0.04 | Why? |
| Glutathione Peroxidase | 1 | 2016 | 83 | 0.04 | Why? |
| Factor Xa | 1 | 2017 | 113 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Platelet Aggregation | 1 | 2018 | 318 | 0.04 | Why? |
| Chest Pain | 1 | 2020 | 578 | 0.04 | Why? |
| Immunoglobulins | 1 | 2021 | 811 | 0.04 | Why? |
| Patients' Rooms | 1 | 2021 | 675 | 0.04 | Why? |
| Hemostatics | 1 | 2017 | 142 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Blood Coagulation Factors | 1 | 2017 | 223 | 0.04 | Why? |
| CHO Cells | 1 | 2017 | 831 | 0.04 | Why? |
| Troponin | 1 | 2021 | 1058 | 0.04 | Why? |
| Cell Cycle Proteins | 1 | 2017 | 297 | 0.04 | Why? |
| Transforming Growth Factor beta | 1 | 2017 | 363 | 0.04 | Why? |
| Cricetulus | 1 | 2017 | 936 | 0.04 | Why? |
| Chemokines | 1 | 2021 | 1095 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Arginine | 1 | 2017 | 377 | 0.03 | Why? |
| Nuclear Proteins | 1 | 2017 | 321 | 0.03 | Why? |
| Intensive Care Units, Pediatric | 1 | 2021 | 1098 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| Platelet Activation | 1 | 2018 | 660 | 0.03 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Angiogenesis Inhibitors | 1 | 2017 | 395 | 0.03 | Why? |
| Rivaroxaban | 1 | 2017 | 467 | 0.03 | Why? |
| Ventricular Function, Left | 1 | 2021 | 1555 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2017 | 584 | 0.03 | Why? |
| Platelet Count | 1 | 2018 | 1381 | 0.03 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Precision Medicine | 1 | 2021 | 1477 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Cricetinae | 1 | 2017 | 3344 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.02 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.02 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.02 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.02 | Why? |
| Health Surveys | 1 | 2019 | 2841 | 0.02 | Why? |
| Tobacco | 1 | 2009 | 274 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.02 | Why? |
| Hemodynamics | 1 | 2013 | 1562 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Societies, Medical | 1 | 2019 | 6907 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Emergency Medical Services | 1 | 2019 | 3557 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Registries | 1 | 2019 | 12327 | 0.01 | Why? |
| Hypoxia | 1 | 2013 | 3626 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Smoking | 1 | 2009 | 3358 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2013 | 10998 | 0.01 | Why? |
| Stroke | 1 | 2017 | 8839 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |